Announcing FierceDrugDelivery

Today we launch FierceDrugDelivery--and our mission to readers is to be the first place to turn for drug delivery industry news and insight.

Click here to activate your complimentary subscription to FierceDrugDelivery.

FierceDrugDelivery is published weekly on Wednesdays via e-mail newsletter, and stories will be posted on FierceDrugDelivery.com as news breaks throughout the week.

Drug delivery systems are fundamental to the industries we cover across the Fierce portfolio--from discovery to postmarketing. FierceBiotech readers I've spoken to understand advancements in drug delivery systems enable viable development of new classes of breakthrough therapies. FiercePharma readers expect drug delivery technologies to increase dosage efficacy and decrease toxicity, dramatically improving both the regulatory approval process and lifecycles of their products. 

We're thrilled to have John Haystead as lead editor of FierceDrugDelivery. He's a former Editor-in-Chief of Pharmaceutical Technology magazine and brings a wealth of drug delivery knowledge to our team. Drug delivery industry executives and influencers with news and tips should e-mail him directly: [email protected]

FierceDrugDelivery is made possible by the support of Elan Drug Technologies. Thanks to their exclusive charter sponsorship, readers can enjoy complimentary drug delivery industry news and analysis alongside their current Fierce subscriptions. 

Click here to activate your complimentary subscription to FierceDrugDelivery.

- Arsalan Arif (e-mail | twitter)
Group Publisher, FierceMarkets Life Sciences

PS: Are you attending the BIO International Convention next week in Chicago? Drop me a line or follow me on twitter--our team relies on reader feedback and we'd love to hear from you at the show.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.